Theranostics Finances and Coding of Today and a Look Forward

The field of theranostics is experiencing rapid growth, driven by the expanding pipeline of radiopharmaceutical therapies and increasing clinical demand. This paper provides a comprehensive overview of the current financial landscape, coding and reimbursement strategies, and long-term planning considerations required to financially support clinical theranostics programs in the United States. Emphasis is placed on accurate Current Procedural Terminology and Healthcare Common Procedure Coding System coding, engagement with stakeholders, and the importance of compliance, billing accuracy, and infrastructure investment. Key areas such as dosimetry, amino acid infusion billing, Evaluation and Management codes, and leverage of 340B pricing are explored. The paper also outlines tools and resources available to support correct coding and operational success and provides guidance for projecting a 5-y budget necessary for scaling programs to meet anticipated global market growth of and patient demand for theranostics. The goal is to equip nuclear medicine and theranostics professionals and hospital leaders with practical insights for building financially viable and sustainable theranostics programs that can meet future demand.